Overview
This conference will focus on two major developments currently affecting Paediatric Development: Innovative approaches to Drug Development and the impact of the current environment on the Regulatory and Research Infrastructure. You will gain critical insights from Regulators and leading industry experts about the latest scientific innovations and have the opportunity to engage in lively discussions with Paediatric Committee (PDCO) members and other industry experts involved in paediatric drug development. The patient experience will be voiced throughout the conference.
Program Committee
-
Heidrun Hildebrand Paediatric Development Alliance Manager, Paediatric Medicine; Research and De
BAYER, Germany -
Mette Due Theilade Thomsen, PhD CEO
PIP Adviser, Denmark -
Geneviève Le Visage, PharmD, MSc Head EU RA Policy and Liaison
Novartis Pharma AG, Switzerland -
Dimitrios Athanasiou, MBA Patient Advocate
WORLD DUCHENNE ORGANIZATION (WDO) , MDA HELLAS, Greece -
Martine Dehlinger-Kremer, PhD VP Scientific Affairs, Pediatric SME, ICON Plc & President, EUCROF
Icon Plc, Germany -
Siri Wang Scientific Director; PDCO delegate
Norwegian Medical Products Agency, Norway
Have an account?